ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

valbenazine

Also written as “Valbenazine”, “NBI-98854” and “MT-5199”.

Its studies are mostly in Tardive Dyskinesia · Tourette Syndrome · Schizophrenia · Huntington Disease · Dyskinesias, led by 2 companies.

Drug pageValbenazine: every studyAll 33 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 4, 201828 company-led studies, 2 open or runningNext primary completion: Apr 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences272 open or runningphase 4since Oct 4, 2018Dec 21, 2010Apr 2028phase 3 · NCT06312189
Tanabe Pharmaits history only10 open or runningphase 3since Jun 2, 2017Jun 2, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Neurocrine Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Dec 21, 2010.

  1. Feb 19, 2018Phase 2 study in Tourette SyndromeNCT03444038 · 85 enrolled · United States, Puerto Rico
  2. May 8, 2018Phase 2 study in Tourette SyndromeNCT03530293 · 81 enrolled · United States, Puerto Rico
  3. Oct 4, 2018Phase 4 study in Tardive DyskinesiaNCT03698331 · 89 enrolled · United States, Puerto Rico
  4. Nov 5, 2018Phase 2 study in Tourette SyndromeNCT03732534 · 6 enrolled · United States, Puerto Rico
  5. Mar 25, 2019Phase 4 study in Tardive DyskinesiaNCT03891862 · 135 enrolled · United States, Puerto Rico
  6. Sep 23, 2019Phase 3 study in Huntington DiseaseNCT04102579 · 128 enrolled · United States, Canada
  7. May 19, 2020Phase 3 study in Huntington DiseaseNCT04400331 · 154 enrolled · United States, Canada
  8. Oct 26, 2021Phase 3 study in SchizophreniaNCT05110157 · 442 enrolled · United States, Argentina, Bulgaria and more
  9. Jan 10, 2022Phase 3 study in DyskinesiasNCT05206513 · 86 enrolled · United States, Argentina, Belgium and more
  10. Dec 8, 2022Phase 3 study in SchizophreniaNCT05654870 · 8 enrolled · United States
  11. May 5, 2023Phase 4 study in SchizophreniaNCT05859698 · 59 enrolled · United States
  12. Mar 8, 2024Phase 3 study in Huntington DiseaseNCT06312189 · 7 planned · Canada
  13. Jul 29, 2025Phase 4 study in SchizophreniaNCT07105111 · 100 planned · United States
  14. Nov 3, 2026Phase 3 study terminatedStudy stoppedNCT04400331 · “Sponsor Decision”

Ahead

  1. Apr 2028Primary completion: phase 3 study in Huntington DiseaseNCT06312189
  2. Jun 2028Primary completion: phase 4 study in SchizophreniaNCT07105111

TargetBeta

SLC18A2 →read by rule
“Synaptic vesicular amine transporter inhibitor; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule

Other programs on SLC18A2

ProgramCompanyFurthest phaseStudies
lisdexamfetamineruleTakedaphase 447
deutetrabenazineruleTeva Pharmaceutical Industriesphase 412

Studies

All 27 Neurocrine Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07105111Schizophrenia · United States4RecruitingJun 2028100
NCT06312189Huntington Disease · Canada3By invitationApr 20287
NCT05859698Schizophrenia · United States4CompletedDec 27, 202459
NCT05654870Schizophrenia · United States3TerminatedNov 8, 20238
NCT05206513Dyskinesias · United States, Argentina, Belgium and more3CompletedOct 16, 202586
NCT05110157Schizophrenia · United States, Argentina, Bulgaria and more3CompletedFeb 4, 2025442
NCT04400331Huntington Disease · United States, Canada3TerminatedNov 5, 2025154
NCT04102579Huntington Disease · United States, Canada3CompletedOct 15, 2021128
NCT03891862Tardive Dyskinesia · United States, Puerto Rico4CompletedDec 23, 2019135
NCT03732534Tourette Syndrome · United States, Puerto Rico2TerminatedFeb 18, 20196
NCT03698331Tardive Dyskinesia · United States, Puerto Rico4CompletedApr 3, 201989
NCT03530293Tourette Syndrome · United States, Puerto Rico2TerminatedJul 16, 201981
NCT03444038Tourette Syndrome · United States, Puerto Rico2CompletedJul 12, 201985
NCT03325010Tourette Syndrome · United States, Puerto Rico2CompletedNov 1, 2018127
NCT02879578Tourette Syndrome · United States2CompletedNov 1, 2017155
NCT02736955Tardive Dyskinesia · United States3CompletedJun 30, 2017161
NCT02679079Tourette Syndrome · United States2CompletedApr 14, 201798
NCT02581865Tourette Syndrome · United States2CompletedDec 2016124
NCT02405091Tardive Dyskinesia · United States, Canada, Puerto Rico3CompletedMar 2017167
NCT02274558Tardive Dyskinesia · United States, Canada, Puerto Rico3CompletedSep 2015234
NCT02256475Tourette Syndrome · United States1CompletedNov 201536
NCT01916993Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects · United States1CompletedDec 201324
NCT01910480Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects · United States1CompletedAug 201324
NCT01733121Tardive Dyskinesia · United States, Puerto Rico2CompletedDec 2013102
NCT01688037Tardive Dyskinesia · United States, Puerto Rico2CompletedSep 2013109
NCT01393600Tardive Dyskinesia · United States2CompletedFeb 201237
NCT01267188Tardive Dyskinesia · Canada2CompletedMar 201110

How it is read

Names in the registry

  • “Valbenazine”, 15 entries
  • “NBI-98854”, 13 entries
  • “MT-5199”, 1 entry
  • “NBI-98854 50 mg capsule”, 1 entry
  • “NBI-98854 50 mg capsule once daily”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.